How PSK Works: Mechanisms of Anti-Cancer Action

PSK and PSP: Turkey Tail

TLR2: the specific immune receptor PSK binds

Lu and colleagues proved PSK's anti-tumor effect via TLR2: in mice with TLR2 genetically removed, oral PSK no longer inhibited breast cancer tumor growth. The receptor mechanism is not theoretical; it has been experimentally validated.

Lu et al., Clinical Cancer Research, 2011

CD8+ T + NK cells

the immune cells TLR2 activation recruits against tumors, proven in vivo

G0/G1 arrest

how PSK stops cancer cells from dividing, independent of immune activity

Trastuzumab synergy

PSK-activated NK cells enhanced Herceptin's anti-tumor effect in laboratory studies

Lu et al., Clinical Cancer Research, 2011

View as image ↗

PSK (Polysaccharide-K, brand name Krestin) is not described as "anti-cancer" because it loosely supports the immune system. It has a specific molecular mechanism at a specific receptor, confirmed in studies that tested what happens when that receptor is removed. The mechanism was identified precisely enough to show that PSK can enhance the effect of a modern targeted cancer drug.

This level of mechanistic clarity separates PSK from most mushroom-derived compounds. Most mushroom extracts have demonstrated some immune activity in cell culture or vague tumor-slowing effects in animal models. PSK has a named receptor (TLR2), a documented immune cascade (TLR2 to dendritic cells to IL-12 to CD8+ T cells and NK cells), a proof-of-mechanism via receptor knockout, and a preliminary synergy finding with pharmaceutical cancer therapies. It also works directly on cancer cells through a separate pathway, independent of the immune mechanism.

For context on what PSK is, where it comes from, and its clinical history in Japan, see PSK (Krestin): the most successful mushroom-derived drug. For the broader beta-glucan context, see what are beta-glucans: the most important compound in medicinal mushrooms.

Two Pathways, Simultaneously Active

PSK's anti-cancer activity runs through two separate biological pathways that operate at the same time. Understanding both is important because they work on different targets and are relevant to different clinical situations.

Pathway 1: Immune activation through TLR2. PSK binds to Toll-like receptor 2 on immune cells. This binding triggers a cascade that ultimately activates the immune cells most important for fighting cancer: CD8+ cytotoxic T cells (which directly kill cells that display tumor markers) and NK cells (natural killer cells, which kill tumors without prior sensitization). The cascade runs through dendritic cells and IL-12 production. This pathway acts on the immune system, not the tumor itself, and requires a functional immune system to work.

Pathway 2: Direct cytotoxicity in cancer cells. PSK enters cancer cells or acts on their surface and arrests their division cycle, preventing them from reproducing. It also induces apoptosis (programmed cell death) in cancer cells. This pathway acts on tumor cells directly and does not require immune system involvement.

Both pathways have research support at different evidence levels, and both are likely contributing to PSK's clinical effects in cancer patients. The immune pathway is better characterized mechanistically; the direct cytotoxicity pathway is well documented in cell culture but less thoroughly studied in vivo.

TLR2: What It Is and Why PSK Binding to It Matters

TLR2 (Toll-like receptor 2) is a pattern recognition receptor, a molecular sensor on immune cell surfaces that detects structural patterns associated with pathogens and damaged tissue. When TLR2 is activated, it triggers an innate immune response, initiating the first line of defense against perceived threats.

Most beta-glucans from fungi activate immune cells through receptors like dectin-1. PSK's selectivity for TLR2 rather than the standard beta-glucan receptor is one reason its mechanism is distinct. TLR2 activation leads to a specific downstream outcome: dendritic cells become activated, mature, and migrate to lymph nodes where they present antigen to T cells.

Lu and colleagues demonstrated PSK's TLR2 binding directly in 2011, published in Clinical Cancer Research.^[1] The key evidence was the receptor knockout experiment: they tested oral PSK in normal mice bearing breast cancer tumors, and in mice engineered to lack TLR2 (TLR2-knockout mice). In normal mice, oral PSK inhibited tumor growth. In TLR2-knockout mice, the anti-tumor effect was completely absent.

This is not just a positive correlation. It is direct loss-of-function evidence: remove the receptor, lose the effect. This level of mechanistic proof is uncommon in mushroom compound research. Most studies show a correlation between compound and outcome; the Lu 2011 TLR2 knockout establishes causation at the receptor level.

The downstream cascade from TLR2 activation: activated dendritic cells produce IL-12, a cytokine that primes CD8+ T cells (cytotoxic T lymphocytes) and activates NK cells. CD8+ T cells, once primed, can directly kill cancer cells bearing specific tumor antigens. NK cells kill cancer cells that have lost surface markers, a hallmark of many tumor types that allows them to evade T cell recognition. Both populations increased in PSK-treated mice, and both were necessary for the anti-tumor effect.

The Trastuzumab Synergy: A Finding With Clinical Implications

The second Lu 2011 study from the same group extended the TLR2 finding in a different direction.^[2] The researchers asked whether PSK-activated NK cells could enhance the effect of trastuzumab (Herceptin), the HER2-targeted monoclonal antibody widely used in HER2-positive breast cancer.

Trastuzumab works partly through antibody-dependent cellular cytotoxicity (ADCC): NK cells recognize tumor cells coated with antibody and kill them. The efficiency of this process depends on how active the NK cells are. If PSK activates NK cells via TLR2, it could potentially increase the ADCC response when combined with trastuzumab.

The laboratory finding confirmed this logic: PSK activated human NK cells in vitro, and the combined PSK plus trastuzumab produced significantly greater cancer cell killing than trastuzumab alone.

This is an in vitro result, not clinical trial data. Whether the same synergy occurs in patients receiving chemotherapy and trastuzumab alongside PSK has not been tested in a controlled trial. But it establishes a specific, mechanistically grounded hypothesis for why PSK might be particularly useful as an adjuvant in HER2+ cancer treatment, and it connects PSK's basic mechanism to the targeted cancer drug landscape.

Direct Cytotoxicity: What Happens Inside the Cancer Cell

Separate from immune activation, PSK exerts direct effects on cancer cells. This was documented in the early comprehensive review of PSK mechanisms by Fisher and Yang in 2002 and has been confirmed in subsequent mechanistic work.^[3]

The primary direct mechanism is cell cycle arrest. Cells divide through a sequence of phases: G1 (preparation), S (DNA copying), G2 (second preparation), and M (division). PSK arrests cancer cells in G0/G1, the very beginning of the cycle, preventing them from proceeding to DNA replication. A cell stuck in G0/G1 cannot divide. If it cannot divide, the tumor cannot grow.

Alongside cell cycle arrest, PSK induces apoptosis (the programmed cell death process that healthy cells use to eliminate damaged or abnormal cells). Habtemariam's 2020 comprehensive review documented this mechanism across multiple cancer cell types studied in laboratory settings.^[4] PSK also shifts the immune response from Th2 (which favors tumor tolerance) toward Th1 (which favors tumor elimination) through increased IL-12 production, a finding that bridges the immune and direct mechanisms.

The direct cytotoxicity effects are well established in cell culture. Their relevance in a clinical setting, where PSK is administered orally and must survive gastrointestinal processing and reach tumor tissue at sufficient concentration, is less certain. The oral bioavailability question applies to the direct mechanism more than to the immune mechanism, since the immune pathway only requires PSK to reach immune cells in the gut wall and lymphoid tissue.

Immune Recovery: PSK Against Tumor-Induced Immunosuppression

Cancer patients face a compounding problem: the tumor itself suppresses the immune system. Tumors secrete TGF-beta (transforming growth factor-beta), a cytokine that normally limits inflammation but is hijacked by tumors to reduce the immune surveillance that would otherwise eliminate them. Chemotherapy further suppresses immune function as a side effect.

Maehara and colleagues reviewed PSK's mechanisms specifically in the context of cancer patients and identified reversal of TGF-beta immunosuppression as a central therapeutic action.^[5] PSK normalizes TGF-beta levels in cancer patients, helping restore immune competence. Maehara's review also covered PSK's effects on IL-15 (a cytokine that promotes NK cell survival and proliferation) and the Th1/Th2 balance correction, all pointing to PSK's role in recovering immune function that cancer and chemotherapy have suppressed.

This immune recovery function may be why PSK consistently shows clinical benefit in combination with chemotherapy rather than alone. Chemotherapy directly suppresses the immune system as it kills cancer cells; PSK partially counteracts this suppression while the chemotherapy addresses the tumor. The net effect is that the immune system remains more functional during treatment, which may explain both the reduced toxicity and the improved survival outcomes documented in meta-analyses.

The PSP Comparison: Same Mushroom, Different Mechanism

PSP (Polysaccharide-Peptide, the Chinese counterpart to PSK) comes from a different strain of the same turkey tail mushroom but acts through different primary immune cell targets.

Sekhon and colleagues demonstrated in 2013 that PSP primarily activates monocytes in resting human peripheral blood mononuclear cells.^[6] Monocytes are precursor cells to macrophages and dendritic cells, but they are not the same as the CD8+ T cells and NK cells that PSK primarily activates via TLR2. PSP's activation of monocytes provides an immunological rationale for its activity but represents a different entry point into the immune system than PSK's TLR2 pathway.

This mechanistic distinction matters for understanding why the two compounds from the same mushroom have been developed and studied separately. They are not interchangeable. For a full comparison of PSK and PSP's structures, sources, and evidence bases, see PSP vs. PSK: comparing turkey tail's two major compounds.

For more on how mushroom polysaccharides generally fight cancer through multiple mechanisms, see how mushroom polysaccharides kill cancer cells: four distinct mechanisms. For the clinical trial record that this mechanism supports, see the history of PSK: from Japanese lab to cancer clinic and PSK and PSP: how Japan turned turkey tail into a billion-dollar cancer drug. For how PSK compares mechanistically to reishi polysaccharides in cancer, see Ganoderma lucidum as a cancer adjunct: clinical evidence.

The Bottom Line

PSK's anti-cancer mechanism operates through two simultaneous pathways. The primary pathway is immune activation via TLR2: PSK binds Toll-like receptor 2, triggering dendritic cell maturation, IL-12 production, and activation of CD8+ cytotoxic T cells and NK cells. TLR2-knockout mice proved this receptor is required for the anti-tumor effect. A secondary finding showed PSK-activated NK cells enhance trastuzumab's HER2 cancer-killing effect. The direct cytotoxicity pathway arrests cancer cells in G0/G1 and induces apoptosis independently of immune involvement. PSK also reverses TGF-beta-mediated immunosuppression, restoring immune function that tumors and chemotherapy suppress. PSP, from a different turkey tail strain, activates monocytes rather than T cells and NK cells.

Frequently Asked Questions

How does PSK kill cancer cells?

Through two simultaneous pathways. The primary pathway: PSK binds TLR2 receptors on immune cells, activating dendritic cells that produce IL-12, which primes CD8+ cytotoxic T cells and NK cells to kill tumor cells. The secondary pathway: PSK directly arrests cancer cells in the G0/G1 phase of the cell division cycle and induces apoptosis, preventing tumor cells from replicating. Both mechanisms are documented in laboratory research; the TLR2 pathway has been proven via receptor knockout experiments.

What is TLR2 and why does it matter for cancer treatment?

TLR2 (Toll-like receptor 2) is a pattern recognition receptor on immune cell surfaces that detects structural patterns associated with pathogens. When PSK binds TLR2, it triggers innate immune activation including dendritic cell maturation, IL-12 production, and activation of cytotoxic T cells and NK cells, all relevant to anti-tumor immunity. The clinical relevance is that PSK's immune activation is receptor-specific, not a general immune stimulant. Removing TLR2 (in knockout mice) completely abolishes PSK's anti-tumor effect, proving this receptor is the entry point for the mechanism.

Does PSK boost NK cell activity?

Yes. NK cell activation is a confirmed downstream consequence of PSK's TLR2 binding cascade. Lu and colleagues demonstrated this in both animal models and human immune cell studies. In the trastuzumab synergy experiment, PSK activated human NK cells in vitro, and the combination with trastuzumab (which also relies on NK cell activity for ADCC) produced significantly greater cancer cell killing than trastuzumab alone. NK cells are one of two primary immune populations (alongside CD8+ T cells) through which PSK's anti-tumor immune activity is mediated.

What is the mechanism of action of Krestin?

Krestin (PSK) has a dual mechanism of action. Immunologically: it selectively agonizes TLR2 on immune cells, triggering dendritic cell activation, IL-12 secretion, and priming of CD8+ cytotoxic T cells and NK cells against tumor targets. It also reverses TGF-beta-mediated immunosuppression and shifts the Th1/Th2 balance toward Th1 (anti-tumor). Directly on cancer cells: it induces G0/G1 cell cycle arrest and apoptosis, preventing tumor cell replication. These two pathways operate simultaneously in cancer patients receiving PSK as an adjuvant alongside chemotherapy.

Does PSK work directly on cancer cells or through the immune system?

Both. The immune mechanism (TLR2 activation, T cell and NK cell recruitment) is the primary mechanism at the receptor level. The direct mechanism (G0/G1 arrest, apoptosis in cancer cells) is a secondary pathway documented in cell culture studies. In clinical settings, the immune pathway is more certain to be active because oral PSK can reach gut-associated immune cells even if it does not reach tumor tissue in high concentrations. The direct cytotoxicity may be a contributing factor but depends on PSK's bioavailability and distribution to tumor sites.

Sources & References

1. 1RTHM-00419·Lu, Hailing et al. (2011). “Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells..” Clinical cancer research : an official journal of the American Association for Cancer Research.Study breakdown →PubMed →↩
2. 2RTHM-00420·Lu, Hailing et al. (2011). “TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy..” Clinical cancer research : an official journal of the American Association for Cancer Research.Study breakdown →PubMed →↩
3. 3RTHM-00089·Fisher, Monte et al. (2002). “Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy..” Anticancer research.Study breakdown →PubMed →↩
4. 4RTHM-01194·Habtemariam, Solomon (2020). “Trametes versicolor (Synn. Coriolus versicolor) Polysaccharides in Cancer Therapy: Targets and Efficacy..” Biomedicines.Study breakdown →PubMed →↩
5. 5RTHM-00475·Maehara, Yoshihiko et al. (2012). “Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives..” Surgery today.Study breakdown →PubMed →↩
6. 6RTHM-00552·Sekhon, Bhagwant Kaur et al. (2013). “PSP activates monocytes in resting human peripheral blood mononuclear cells: immunomodulatory implications for cancer treatment..” Food chemistry.Study breakdown →PubMed →↩